PMC:7076992 / 3871-4492 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T11","span":{"begin":45,"end":59},"obj":"Body_part"},{"id":"T12","span":{"begin":281,"end":287},"obj":"Body_part"},{"id":"T13","span":{"begin":499,"end":505},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"It should be noted that treatment with human immunoglobulin has been associated with significantly increased same-day thrombotic event risk (0.04 to 14.9%) [8]. These data indicate the potential value of evaluating the effectiveness of early intervention therapy with convalescent plasma or SARS-CoV-2-specific hyperimmune globulin in patients with acute respiratory disease in this outbreak. Given the lack of knowledge on the basic biology of SARS-CoV-2, including virus variability and mutation, plasma collected locally may better reflect the circulating virus in the population and could be a valid treatment option."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T21","span":{"begin":291,"end":299},"obj":"Disease"},{"id":"T22","span":{"begin":355,"end":374},"obj":"Disease"},{"id":"T23","span":{"begin":445,"end":453},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005087"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"It should be noted that treatment with human immunoglobulin has been associated with significantly increased same-day thrombotic event risk (0.04 to 14.9%) [8]. These data indicate the potential value of evaluating the effectiveness of early intervention therapy with convalescent plasma or SARS-CoV-2-specific hyperimmune globulin in patients with acute respiratory disease in this outbreak. Given the lack of knowledge on the basic biology of SARS-CoV-2, including virus variability and mutation, plasma collected locally may better reflect the circulating virus in the population and could be a valid treatment option."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T25","span":{"begin":39,"end":44},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T26","span":{"begin":60,"end":63},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T27","span":{"begin":281,"end":287},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T28","span":{"begin":467,"end":472},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T29","span":{"begin":499,"end":505},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T30","span":{"begin":559,"end":564},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T31","span":{"begin":596,"end":597},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"It should be noted that treatment with human immunoglobulin has been associated with significantly increased same-day thrombotic event risk (0.04 to 14.9%) [8]. These data indicate the potential value of evaluating the effectiveness of early intervention therapy with convalescent plasma or SARS-CoV-2-specific hyperimmune globulin in patients with acute respiratory disease in this outbreak. Given the lack of knowledge on the basic biology of SARS-CoV-2, including virus variability and mutation, plasma collected locally may better reflect the circulating virus in the population and could be a valid treatment option."}

{"project":"LitCovid-sentences","denotations":[{"id":"T30","span":{"begin":0,"end":160},"obj":"Sentence"},{"id":"T31","span":{"begin":161,"end":392},"obj":"Sentence"},{"id":"T32","span":{"begin":393,"end":621},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It should be noted that treatment with human immunoglobulin has been associated with significantly increased same-day thrombotic event risk (0.04 to 14.9%) [8]. These data indicate the potential value of evaluating the effectiveness of early intervention therapy with convalescent plasma or SARS-CoV-2-specific hyperimmune globulin in patients with acute respiratory disease in this outbreak. Given the lack of knowledge on the basic biology of SARS-CoV-2, including virus variability and mutation, plasma collected locally may better reflect the circulating virus in the population and could be a valid treatment option."}

{"project":"2_test","denotations":[{"id":"32178711-23907744-23646626","span":{"begin":157,"end":158},"obj":"23907744"}],"text":"It should be noted that treatment with human immunoglobulin has been associated with significantly increased same-day thrombotic event risk (0.04 to 14.9%) [8]. These data indicate the potential value of evaluating the effectiveness of early intervention therapy with convalescent plasma or SARS-CoV-2-specific hyperimmune globulin in patients with acute respiratory disease in this outbreak. Given the lack of knowledge on the basic biology of SARS-CoV-2, including virus variability and mutation, plasma collected locally may better reflect the circulating virus in the population and could be a valid treatment option."}

{"project":"LitCovid-PubTator","denotations":[{"id":"91","span":{"begin":39,"end":44},"obj":"Species"},{"id":"92","span":{"begin":291,"end":301},"obj":"Species"},{"id":"93","span":{"begin":335,"end":343},"obj":"Species"},{"id":"94","span":{"begin":445,"end":455},"obj":"Species"},{"id":"95","span":{"begin":349,"end":374},"obj":"Disease"}],"attributes":[{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"Tax:9606"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"Tax:2697049"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"Tax:9606"},{"id":"A94","pred":"tao:has_database_id","subj":"94","obj":"Tax:2697049"},{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"MESH:D012120"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"It should be noted that treatment with human immunoglobulin has been associated with significantly increased same-day thrombotic event risk (0.04 to 14.9%) [8]. These data indicate the potential value of evaluating the effectiveness of early intervention therapy with convalescent plasma or SARS-CoV-2-specific hyperimmune globulin in patients with acute respiratory disease in this outbreak. Given the lack of knowledge on the basic biology of SARS-CoV-2, including virus variability and mutation, plasma collected locally may better reflect the circulating virus in the population and could be a valid treatment option."}